Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.
The iShares Biotechnology ETF (IBB) climbed up 1.9%.
In corporate news, Eli Lilly (LLY) said data from a phase 3 head-to-head trial showed retatrutide delivered greater A1C reduction and "substantially" more weight loss than Novo Nordisk's (NVO) injectable Ozempic 2 mg in adults with type 2 diabetes at 80 weeks. Lilly shares were up 0.5%, and Novo was down 1.4%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments